UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 24, 2004
Vicuron Pharmaceuticals Inc.
(Exact Name of Registrant As Specified in its Charter)
Delaware | 000-31145 | 04-3278032 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Nu mber) |
455 South Gulph Road, Suite 305, King of Prussia, PA 19406
(Address of Principal Executive Offices) (Zip Code)
(610) 205-2300
(Registrants telephone number, including area code)
not applicable
(Former Name or Former Address, if Changed Since Last Report.)
Item 5. Other Events.
On May 24, 2004, Vicuron Pharmaceuticals Inc. announced that it received an approvable letter from the U.S. Food and Drug Administration. However, the letter indicated that Vicurons New Drug Application submission for anidulafungin does not currently support a labeling claim for the initial treatment of esophageal candidiasis.
A copy of the press release relating to such announcement is attached to this Current Report on Form 8-K as Exhibit 99.1
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
VICURON PHARMACEUTICALS INC. | ||||
(Registrant) | ||||
Date: May 27, 2004 |
By: |
/s/ George F. Horner III | ||
George F. Horner III | ||||
President and Chief Executive Officer |
EXHIBIT INDEX
Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibit.
Exhibit No. |
Description | |
99.1 | Press release of Vicuron Pharmaceuticals Inc. dated May 24, 2004. |